Embolism - peripheral
Methodology & AI Transparency ⓘ
Embolism - peripheral Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as I74.4, Embolism - peripheral falls under Blood Pressure management, where vascular stiffness assessment [Embolism - peripheral I74.4] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Embolism - peripheral uses ICD-10 I74.4 across Blood Pressure specialty care.
- 3 Typical cash cost range: Workup highlights for Embolism - peripheral (I74.4): vascular stiffness assessment [Embolism - peripheral I74.4].
- 4 Top reported side effects / signs: Key Blood Pressure biomarkers for Embolism - peripheral (I74.4): Urine Albumin-to-Creatinine Ratio [Embolism - peripheral I74.4] & Home Seated Blood in Embolism - peripheral (I74.4: Pressure) (< 120/75 mmHg (I74.4)).
Ask our AI Specialists anything about Embolism - peripheral
What Is Embolism - peripheral?
Designated in federal medical registries as I74.4, Embolism - peripheral falls under Blood Pressure management, where vascular stiffness assessment [Embolism - peripheral I74.4] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Embolism - peripheral (I74.4, Blood Pressure) reflects intimal-medial vascular remodeling [Embolism - peripheral I74.4]. longitudinal control is benchmarked via Urine Albumin-to-Creatinine Ratio [Embolism - peripheral I74.4].
Common Symptoms & Clinical Signs
- • Presentation of Embolism - peripheral (I74.4): localized extremity swelling, in Embolism - peripheral (I74.4: warmth, or venous)
- • Secondary Embolism - peripheral clinical sign: cold distal extremities in Embolism - peripheral (I74.4: or diminished peripheral)
- • Symptom flares in Embolism - peripheral correlating with Urine Albumin-to-Creatinine Ratio [Embolism - peripheral I74.4] deviation outside < 15 mg/g (I74.4)
- • Functional blood pressure impact requiring vascular stiffness assessment [Embolism - peripheral I74.4] evaluation (I74.4)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Embolism - peripheral Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I74.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio [Embolism - peripheral I74.4] | < 15 mg/g (I74.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Home Seated Blood in Embolism - peripheral (I74.4: Pressure) | < 120/75 mmHg (I74.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Embolism - peripheral I74.4] | 1.00 – 1.30 (I74.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Embolism - peripheral
Treatment selection for Embolism - peripheral depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Embolism - peripheral)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Risk of Venous Thromboembolism with Statins: Evidence Gathered via a Network: What a 137,940-Participant Study Found Rosuvastatin is significantly reduces the risk of VTE when compared with a placebo, other statin subtypes, and fibrate. Balkan medical journal • 2023-09-11 • Meta-Analysis | N = 137,940 | 99/100 | PMID 37519020 ↗ |
| New Insights on Safety Profile of Bremelanotide Across the Clinical Development: What a 1,247-Participant Study Found Although not deemed clinically important, bremelanotide should be used with caution in patients at risk of heart and blood vessel disease, and blood pressure should be well controlled during treatment. Journal of women's health (2002) • 2022-02-15 • Phase III Randomized Trial | N = 1,247 | 96/100 | PMID 35147466 ↗ |
| New Insights on Real-world benefits and safety of direct oral anticoagulants with low molecular: What a 28,112-Participant Study Found DOACs reduce the risk of VTE and DVT following elective THA compared with LMWH without increasing bleeding risk, for UK-licensed agents and doses. The bone & joint journal • 2026-11-01 • Meta-Analysis | N = 28,112 | 94/100 | PMID 42966367 ↗ |
| New Insights on Safety and real-world benefits of ubrogepant in participants with major heart and: What a 311-Participant Study Found The safety and real-world benefits of ubrogepant for the acute treatment of a single migraine attack did not differ by the presence of major heart and blood vessel risk factors. Cephalalgia : an international journal of headache • 2021-08-15 • Phase III Randomized Trial | N = 311 | 93/100 | PMID 33874756 ↗ |
| What the Latest Evidence Really Says About Glucagon-like peptide-1 receptor agonists on mortality and heart and blood vessel The agents of this class appear to reduce all-cause mortality, heart and blood vessel mortality, and the incidence of heart attack at mid-term follow up. International journal of cardiology • 2017-08-01 • Meta-Analysis | Multi-cohort | 92/100 | PMID 28501352 ↗ |
Embolism - peripheral Patient Community & “People Like Me” Threads
Filter Embolism - peripheral community threads and patient logs by age, biological sex, dosage, and treatment duration.